Source: Annual Congress 2009 - COPD: exacerbation and clinical problems
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Ward, A. M. Wood, R. A. Stockley (Birmingham, United Kingdom). Gas exchange is an independent predictor for macrocytosis in alpha-1-antitrypsin deficiency (AATD). Eur Respir J 2009; 34: Suppl. 53, 3476

Member's Comments

No comment yet.

Related content which might interest you: Erythrocyte abnormalities in alpha-1-antitrypsin deficiency (AATD) patients Source: Annual Congress 2009 - COPD: exacerbation and clinical problems Year: 2009 Higher than expected prevalence of alpha-1-antitrypsin deficiency (AATD) may not necessarily impact on airflow, gas exchange or acute exacerbation rate (AER) Source: Annual Congress 2012 - Prevalences and characterstics of obstructive airway disease Year: 2012 Prevalence of alpha-1-antitrypsin deficiency (A1AD) in patients with COPD. Source: Virtual Congress 2021 – COPD burden, epidemiology and management Year: 2021 Mortality in individuals with severe alpha-1-antitrypsin deficiency (PiZZ) Source: Eur Respir J 2006; 28: Suppl. 50, 144s Year: 2006 Occupational exposure in alpha-1-antitrypsin deficiency (AATD) Source: Annual Congress 2008 - COPD and other environment-related lung diseases Year: 2008 Use of measurements of airway resistance in the determination of reversibility in patients with emphysema associated with alpha-1-antitrypsin (A1ATD) deficiency Source: Eur Respir J 2001; 18: Suppl. 33, 205s Year: 2001 Severe alpha-1-antitrypsin deficiency (A1ATD) caused by Q0Ourém mutation: A clinical characterization Source: Annual Congress 2010 - Genetics of obstruction Year: 2010 Tracing down the evolutionary history of Q0Ourém, a rare allele associated with severe alpha-1-antitrypsin deficiency (AATD) Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease? Year: 2009 Aα360: A measure of disease and treatment efficacy in alpha-1-antitrypsin (A1AT) deficiency Source: Annual Congress 2010 - COPD: phenotyping and monitoring Year: 2010 Effect of danazol on acute phase reactants in patients with PiM, PiMZ and PiZ phenotypes for alpha-1-antitrypsin deficiency Source: Eur Respir J 2001; 18: Suppl. 33, 249s Year: 2001 Immune activation in α1 antitrypsin deficiency (AATD) emphysema: Beyond the protease/antiprotease hypothesis Source: Annual Congress 2012 - Mechanistic studies in airway cell biology Year: 2012 Young adult with inherited PiMZ alpha-1-antitrypsin deficiency (A1ATD)-related bronchiectasis: characteristic of blood neutrophils and A1AT protein Source: International Congress 2016 – Translational studies in lung disease Year: 2016 Proteinase 3 activity is present in sputum from subjects with alpha-1-antitrypsin deficiency (AATD) and COPD Source: Annual Congress 2012 - The smoking gun in COPD biology Year: 2012 Symptom/risk assessment in alpha-1-antitrypsin deficiency (AATD) using the 2011 GOLD algorithm Source: Annual Congress 2012 - COPD monitoring in stable disease and during exacerbation Year: 2012 Risk of cancer in individuals with severe alpha-1-antitrypsin deficiency (PiZZ) compared with the Swedish general population Source: Virtual Congress 2020 – Asthma and COPD: How genetic and environment influences its developement? Year: 2020 Severity of lung disease in siblings with α-1-antitrypsin deficiency (AATD) Source: Annual Congress 2008 - COPD Year: 2008 Alpha 1-Antitrypsin deficiency (AATD) in patients with ARDS consequent to SARS-CoV-2 infection. Source: Virtual Congress 2021 – COVID – 19: treatments and predictive factors Year: 2021 Exercise intolerance and lung emphysema in alpha-1 antitrypsin deficiency (AATD) Source: Annual Congress 2010 - Exercise in COPD Year: 2010